Cargando…
AS03(B)-Adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: A Phase 2/3 Randomized, Placebo-Controlled, Observer-Blinded Trial
Background. This phase 2/3, randomized, placebo-controlled, observer-blinded study assessed the immunogenicity, reactogenicity, and safety of an inactivated, split-virion H5N1 influenza vaccine (A/Indonesia/5/2005) in children aged 6 months through 17 years. Methods. Children received 2 influenza va...
Autores principales: | Kosalaraksa, Pope, Jeanfreau, Robert, Frenette, Louise, Drame, Mamadou, Madariaga, Miguel, Innis, Bruce L., Godeaux, Olivier, Izurieta, Patricia, Vaughn, David W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319481/ https://www.ncbi.nlm.nih.gov/pubmed/25293368 http://dx.doi.org/10.1093/infdis/jiu548 |
Ejemplares similares
-
Heterologous Prime-Boost Vaccination Using an AS03(B)-Adjuvanted
Influenza A(H5N1) Vaccine in Infants and Children <3 Years of Age
por: Nolan, Terry, et al.
Publicado: (2014) -
Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial
por: Schuind, Anne, et al.
Publicado: (2015) -
Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial()
por: Yang, William H., et al.
Publicado: (2013) -
Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults
por: Madan, Anuradha, et al.
Publicado: (2016) -
Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6–35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging Study
por: Kim, Joon Hyung, et al.
Publicado: (2021)